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OBJECTIVES: A meta-analyses of the results from three clinical
trials in type 1 diabetes patients showed that insulin detemir
(IDet) based basal-bolus treatment compared to neutral prota-
mine Hagedorn (NPH) insulin based basal-bolus therapy led to
improved HbA1c (0.13% points lower), a decrease in hypogly-
caemic events (by 4%) and lower body mass index (BMI)
(0.21 kg.m-2). METHODS: A published, validated, peer-
reviewed computer simulation model of diabetes (the CORE
Diabetes Model) was used to project short-term results obtained
from the ﬁxed-effects (weighted average) meta-analysis to long-
term clinical and cost outcomes (including life expectancy,
quality adjusted life expectancy, incidence of complications, and
direct medical costs) for IDet versus NPH in type 1 diabetes
patients, when used in combination with either insulin aspart
(IAsp) or human soluble insulin (HSI) as the bolus component of
therapy. Probabilities of complications were derived from land-
mark clinical and epidemiological studies and the costs of treat-
ing complications in Italy were retrieved from published sources.
Total direct costs (complications + treatment costs) for each arm
were projected over patient lifetimes from an Italian Heath
Service perspective. Both costs and clinical outcomes were dis-
counted at 3% annually. RESULTS: Improved glycaemic control,
decreased hypoglycaemic events and lower BMI with IDet-based
basal/bolus therapy led to fewer diabetes-related complications,
an increase in quality-adjusted life expectancy of 0.185 quality-
adjusted life years (QALYs) (7.71  0.09 versus 7.53  0.09
QALYs), increased total lifetime costs/patient of €5,680
(€104,234  2354 versus €98,554  2124), and an incremental
cost-effectiveness ratio of €30,704 per QALY gained. Results
were stable under variation in a range of reasonable assumptions.
CONCLUSION: The increased cost of therapy for IDet versus
NPH is partly offset by reductions in the treatment costs of
complications and, given the associated clinical beneﬁts, leads to
a cost-effectiveness ratio which falls within a range generally
considered to represent excellent value for money (<€50,000/
QALY gained).
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OBJECTIVES: Long-term T2DM outcomes trials have demon-
strated that intensive pharmaceutical therapy improves outcomes
by delaying complications, thus supporting HbA1c targets (the
ADA and EASD currently suggest 7.0%). Achieving such targets
in actual practice is difﬁcult. Whether intensifying treatment to
achieve this goal is socially optimal, however, depends on
whether the beneﬁts compare favorably to incremental therapy
costs. This study estimates the cost-effectiveness in younger,
newly diagnosed T2DM in the US of “treat to goal” therapy
intensiﬁcation at HbA1c 7.0% compared to less strict therapy
intensiﬁcation at 8.5% often seen in actual practice METHODS:
A Markov simulation model of T2DM was used to estimate
health beneﬁts and direct medical care costs for 1000 newly
diagnosed patients, aged 40–50, each simulated 100 times. The
treatment sub-model builds on previous efforts, including
explicit HbA1c goals, treatment failure, dose escalation (half
then maximal doses), and drug switches. The following simpli-
ﬁed algorithm was used: begin with metformin (MET), add sul-
fonylurea (SULF) at 1st treatment failure, discontinue SULF
and add thiazolidinedione (TZD) at 2nd treatment failure, and
ﬁnally discontinue TZD and begin insulin therapy. RESULTS:
Maintaining HbA1c less than 7.0% led to 0.42 additional
quality-adjusted life-years (QALYs) relative to maintaining
HbA1c under 8.5%. Reductions in costs related to micro- and
macrovascular complications offset all but $874 of the medi-
cine cost increases. The corresponding incremental cost per
QALY gained is $2185. CONCLUSION: The joint ADA/EASD
guideline was cost-effective relative to maintaining HbA1c
below 8.5%. Further reﬁnement of the simulated treatment
algorithm will improve the usefulness for public policy
decision-making.
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OBJECTIVES: Although it has been shown that rapid acting
modern insulins such as insulin aspart (IAsp, NovoRapid)
provide a more convenient and predictable onset of action com-
pared to human soluble insulin (HSI), widespread acceptance of
modern insulins will also depend on economic considerations.
The aim of this study was to assess the cost-effectiveness of
switching type 2 diabetes patients receiving HSI to IAsp, with
or without oral hypoglycemic agents, in the Spanish and Italian
settings. METHODS: Short-term data from the PREDICTIVE
(Predictable Results and Experience in Diabetes through Inten-
siﬁcation and Control to Target: an International Variability
Evaluation) study were used to make long-term (35-years) pro-
jections of clinical and cost outcomes using the CORE Diabetes
Model, a published and validated computer simulation model.
Costs expressed in 2006 Euro (€) values and clinical outcomes
were discounted at 3.5% per annum. The analysis was con-
ducted from a third party health care payer perspective.
RESULTS: In the Spanish and Italian settings, treatment with
IAsp was projected to increase patient life expectancy by 0.101
and 0.164 years and to improve quality-adjusted life expect-
ancy by 0.08 and 0.12 quality-adjusted life years (QALYs),
respectively, compared to HSI. Treatment with IAsp was asso-
ciated with a decrease in direct costs in the Spanish setting
(reduced by €1382) and an increase in costs in Italy (€1874)
compared to HSI over patient lifetimes. IAsp was dominant to
HSI in Spain and associated with an incremental cost-
effectiveness ratio of €15,593 per QALY gained in the Italian
setting. CONCLUSION: IAsp treatment was projected to
result in reduced diabetes-related complications and improved
life expectancy compared to HSI in both settings investigated.
The analysis indicated that IAsp would be dominant compared
to HSI in Spain and in Italy would represent good value
for money based on commonly quoted willingness-to-pay
thresholds.
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